Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference
May 17 2019 - 6:00AM
Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in
cellular medicines for inflammatory diseases, today announced an
upcoming corporate presentation to the 2019 RBC Capital Markets
Healthcare Conference being held in New York. The presentation is
scheduled for Wednesday, May 22, 2019 at 1:35 PM EDT.
About Mesoblast Mesoblast Limited (Nasdaq:MESO
ASX: MSB) has leveraged its proprietary technology platform to
establish a broad portfolio of late-stage allogeneic
(off-the-shelf) product candidates with three product candidates in
Phase 3 trials – acute graft versus host disease, chronic heart
failure and chronic low back pain due to degenerative disc disease.
Through a proprietary process, Mesoblast selects rare mesenchymal
lineage precursor and stem cells from the bone marrow of healthy
adults and creates master cell banks, which can be industrially
expanded to produce thousands of doses from each donor that meet
stringent release criteria, have lot to lot consistency, and can be
used off-the-shelf without the need for tissue matching. Mesoblast
has facilities in Melbourne, New York, Singapore and Texas and is
listed on the Australian Securities Exchange (MSB) and on the
Nasdaq (MESO). www.mesoblast.com
For further information, please contact:
Julie Meldrum |
Schond Greenway |
Corporate Communications |
Investor Relations |
T: +61 3 9639 6036 |
T: +1 212 880 2060 |
E: julie.meldrum@mesoblast.com |
E: schond.greenway@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2023 to Apr 2024